Atlas Trials

Boehringer Ingelheim

2,287 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Boehringer Ingelheim

RecordFirmDate
Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects (NCT02175238)Boehringer Ingelheim2014-07-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 (NCT02133482)Boehringer Ingelheim2014-07-01
Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours (NCT02145741)Boehringer Ingelheim2014-06-11
A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration (NCT02121522)Boehringer Ingelheim2014-06-01
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy (NCT02173769)Boehringer Ingelheim2014-06-01
Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers (NCT02161432)Boehringer Ingelheim2014-06-01
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus (NCT02121483)Boehringer Ingelheim2014-06-01
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa (NCT02149303)Boehringer Ingelheim2014-06-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee (NCT02126826)Boehringer Ingelheim2014-05-28
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (NCT02123823)Boehringer Ingelheim2014-05-15
Long-term Observation PMS for Afatinib (NCT02131259)Boehringer Ingelheim2014-05-07
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab (NCT02104947)Boehringer Ingelheim2014-05-06
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects (NCT02121509)Boehringer Ingelheim2014-05-01
Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects (NCT02109679)Boehringer Ingelheim2014-05-01
Afatinib in Subjects With Kidney Dysfunction (NCT02096718)Boehringer Ingelheim2014-05-01
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use (NCT02129192)Boehringer Ingelheim2014-05-01
Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns (NCT02138097)Boehringer Ingelheim2014-05-01
Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy (NCT02140645)Boehringer Ingelheim2014-05-01
Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients (NCT02126865)Boehringer Ingelheim2014-05-01
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers (NCT02102932)Boehringer Ingelheim2014-05-01
Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects (NCT02148107)Boehringer Ingelheim2014-05-01
Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use (NCT02121535)Boehringer Ingelheim2014-04-01
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers (NCT02093819)Boehringer Ingelheim2014-04-01
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects. (NCT02084056)Boehringer Ingelheim2014-04-01
A Study to Investigate the Phototoxic Potential of Faldaprevir (NCT02114671)Boehringer Ingelheim2014-04-01
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets (NCT02106923)Boehringer Ingelheim2014-04-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers (NCT02106247)Boehringer Ingelheim2014-04-01
Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects (NCT02084082)Boehringer Ingelheim2014-04-01
Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809 (NCT02068690)Boehringer Ingelheim2014-03-20
Sequential Expansion of Comparative Effectiveness of Anticoagulants (NCT02081807)Boehringer Ingelheim2014-03-07
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations (NCT02047903)Boehringer Ingelheim2014-03-05
Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers (NCT02036775)Boehringer Ingelheim2014-03-01
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways (NCT02085161)Boehringer Ingelheim2014-03-01
Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events (NCT02096731)Boehringer Ingelheim2014-03-01
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations (NCT02044380)Boehringer Ingelheim2014-03-01
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers (NCT02057835)Boehringer Ingelheim2014-03-01
Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers (NCT02096744)Boehringer Ingelheim2014-03-01
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (NCT02084511)Boehringer Ingelheim2014-03-01
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab (NCT02054481)Boehringer Ingelheim2014-02-01
Pharmacokinetics and Safety in Healthy Volunteers (NCT02045979)Boehringer Ingelheim2014-01-31
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) (NCT02003573)Boehringer Ingelheim2014-01-29
Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (NCT02037165)Boehringer Ingelheim2014-01-21
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers (NCT02030535)Boehringer Ingelheim2014-01-01
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181 (NCT02044406)Boehringer Ingelheim2014-01-01
Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa (NCT02022020)Boehringer Ingelheim2014-01-01
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets (NCT02028767)Boehringer Ingelheim2014-01-01
Interaction of BI 691751 With Itraconazole (NCT02044393)Boehringer Ingelheim2014-01-01
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects (NCT02028780)Boehringer Ingelheim2014-01-01
The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage (NCT02043808)Boehringer Ingelheim2014-01-01
Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers (NCT02044367)Boehringer Ingelheim2014-01-01
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (NCT02009761)Boehringer Ingelheim2013-12-18
Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours (NCT02020577)Boehringer Ingelheim2013-12-01
Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus (NCT02016625)Boehringer Ingelheim2013-12-01
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) (NCT01979952)Boehringer Ingelheim2013-11-26
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML (NCT01957644)Boehringer Ingelheim2013-11-06
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) (NCT02006732)Boehringer Ingelheim2013-11-01
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days (NCT01969747)Boehringer Ingelheim2013-11-01
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) (NCT01964352)Boehringer Ingelheim2013-11-01
Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel (NCT01941615)Boehringer Ingelheim2013-11-01
Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects (NCT01983566)Boehringer Ingelheim2013-11-01
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®. (NCT01947153)Boehringer Ingelheim2013-11-01
Add-on to Micamlo BP Trial (NCT01975246)Boehringer Ingelheim2013-11-01
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known (NCT01971476)Boehringer Ingelheim2013-10-22
Ventilator Adapters for Combivent Respimat (NCT01969539)Boehringer Ingelheim2013-10-14
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets (NCT01975220)Boehringer Ingelheim2013-10-01
Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects. (NCT01965431)Boehringer Ingelheim2013-10-01
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients (NCT01969721)Boehringer Ingelheim2013-10-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469 (NCT01971502)Boehringer Ingelheim2013-10-01
Ipratropium Bromide in Peri-Operative COPD (NCT01943552)Boehringer Ingelheim2013-10-01
Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients (NCT01957657)Boehringer Ingelheim2013-10-01
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers (NCT01958060)Boehringer Ingelheim2013-10-01
Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary (NCT01971086)Boehringer Ingelheim2013-10-01
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation (NCT01953913)Boehringer Ingelheim2013-09-30
Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma (NCT01950273)Boehringer Ingelheim2013-09-27
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) (NCT01895777)Boehringer Ingelheim2013-09-25
Nintedanib (BIBF 1120) in Mesothelioma (NCT01907100)Boehringer Ingelheim2013-09-19
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors (NCT01938846)Boehringer Ingelheim2013-09-05
GLORIA-AF Registry Program (Phase II/III) (NCT01937377)Boehringer Ingelheim2013-09-02
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran (NCT01955720)Boehringer Ingelheim2013-09-01
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus (NCT01947855)Boehringer Ingelheim2013-09-01
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion (NCT01958164)Boehringer Ingelheim2013-09-01
BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis (NCT01958008)Boehringer Ingelheim2013-09-01
Iota-Carrageenan Nasal Spray in Common Cold (NCT01944631)Boehringer Ingelheim2013-09-01
Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers (NCT01917916)Boehringer Ingelheim2013-08-05
Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers (NCT01922349)Boehringer Ingelheim2013-08-01
Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain (NCT01929031)Boehringer Ingelheim2013-08-01
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain (NCT01929044)Boehringer Ingelheim2013-08-01
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) (NCT01853826)Boehringer Ingelheim2013-07-17
A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea (NCT01903356)Boehringer Ingelheim2013-07-11
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) (NCT01897532)Boehringer Ingelheim2013-07-10
A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (NCT01905111)Boehringer Ingelheim2013-07-01
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function (NCT01896297)Boehringer Ingelheim2013-07-01
Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions (NCT01897597)Boehringer Ingelheim2013-07-01
PMS of Trazenta on the Long-term Use as Add-on Therapy (NCT01904383)Boehringer Ingelheim2013-07-01
Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine (NCT01911780)Boehringer Ingelheim2013-07-01
Safety and Tolerability of BI 409306 in Patients With Schizophrenia (NCT01892384)Boehringer Ingelheim2013-06-28
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy (NCT01856478)Boehringer Ingelheim2013-06-07
Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate (NCT01879371)Boehringer Ingelheim2013-06-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus (NCT01874483)Boehringer Ingelheim2013-06-01
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls (NCT01867307)Boehringer Ingelheim2013-06-01
← Previous Next →

Track Boehringer Ingelheim automatically

Every clearance here is in the API, with alerts when new ones post.